{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T13:11:22Z","timestamp":1794834682289,"version":"4.9.1"},"reference-count":46,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2023,12,31]]},"DOI":"10.1080\/13696998.2023.2188844","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T06:50:00Z","timestamp":1678258200000},"page":"445-453","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1"],"prefix":"10.1080","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4417-8321","authenticated-orcid":false,"given":"Vicente","family":"Escudero-Vilaplana","sequence":"first","affiliation":[{"name":"Hospital Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7639-0082","authenticated-orcid":false,"given":"Roberto","family":"Collado-Borrell","sequence":"additional","affiliation":[{"name":"Hospital Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"De Castro","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Paz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3438-6170","authenticated-orcid":false,"given":"Amelia","family":"Insa","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1624-8206","authenticated-orcid":false,"given":"Elena","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"OSI Bilbao-Basurto, Bilbao, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0434-3436","authenticated-orcid":false,"given":"Ivana","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Flores","sequence":"additional","affiliation":[{"name":"Roche Farma S.A, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Arrabal","sequence":"additional","affiliation":[{"name":"Roche Farma S.A, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2809-7399","authenticated-orcid":false,"given":"David","family":"Carcedo","sequence":"additional","affiliation":[{"name":"Hygeia Consulting, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7935-8317","authenticated-orcid":false,"given":"Alba","family":"Manzaneque","sequence":"additional","affiliation":[{"name":"Hospital Universitari M\u00fatua Terrassa, Terrassa, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"key":"e_1_3_6_2_1","unstructured":"World Health Organization. Fact sheets: cancer 2018. World Health Organization; 2018. https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/cancer"},{"key":"e_1_3_6_3_1","unstructured":"World Health Organization. Cancer Today. World Health Organization; 2022. https:\/\/gco.iarc.fr\/today\/home"},{"key":"e_1_3_6_4_1","unstructured":"American Cancer Society. Lung cancer statistics | How common is lung cancer?. American Cancer Society; 2022. https:\/\/www.cancer.org\/cancer\/lung-cancer\/about\/key-statistics.html"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33142"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx222"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.9030"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200927020-00003"},{"key":"e_1_3_6_11_1","unstructured":"European Medicines Agency. Annex 1 \u2013 summary of product characteristics \u2013 atezolizumab 2021. European Medicines Agency; 2021."},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02098-5"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.10.008"},{"key":"e_1_3_6_14_1","unstructured":"Ortega Eslava A Mar\u00edn Gil R Fraga Fuentes MD et\u00a0al. Incluye actualizaci\u00f3n del \u00e1rea econ\u00f3mica del programa madre 4.0. proyecto de investigaci\u00f3n financiado mediante las ayudas a los grupos de la sefh 2014-15. Autores: gu\u00eda Pr\u00e1ctica. Grupos de trabajo SEFH SociedaEspa\u00f1ola de Farmacia Hospitalaria (SEFH). 2016."},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaceta.2009.07.011"},{"key":"e_1_3_6_16_1","volume-title":"Gu\u00eda y recomendaciones Para la realizaci\u00f3n y presentaci\u00f3n de evaluaciones econ\u00f3micas y an\u00e1lisis de impacto presupuestario de medicamentos en el \u00e1mbito del CatSalut","author":"Puig-Junoy J","year":"2014","unstructured":"Puig-Junoy J, Oliva-Moreno J, Trapero-Bertr\u00e1n M, et\u00a0al. Gu\u00eda y recomendaciones Para la realizaci\u00f3n y presentaci\u00f3n de evaluaciones econ\u00f3micas y an\u00e1lisis de impacto presupuestario de medicamentos en el \u00e1mbito del CatSalut. Barcelona: Generalitat de Catalunya Departament de Salut Servei Catal\u00e0 de la Salut; 2014."},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2017.05.005"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e31826b9950"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181f77a6a"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318299243b"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj496"},{"key":"e_1_3_6_24_1","volume-title":"Base de datos del Consejo General de Colegios Oficiales de Farmac\u00e9uticos","author":"Consejo General de Colegios Oficiales de Farmac\u00e9uticos (CGCOF).","year":"2022","unstructured":"Consejo General de Colegios Oficiales de Farmac\u00e9uticos (CGCOF). Base de datos del Consejo General de Colegios Oficiales de Farmac\u00e9uticos. 2022. www.portalfarma.com"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-023-02356-0"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1994"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.09.2150"},{"key":"e_1_3_6_28_1","volume-title":"Healthcare cost database eSalud","author":"Gisbert R","year":"2022","unstructured":"Gisbert R, Brosa M. Healthcare cost database eSalud. Barcelona; 2022. http:\/\/www.oblikue.com\/bddcostes\/"},{"key":"e_1_3_6_29_1","first-page":"524","article-title":"Care costs and activity in the last three months of life of cancer patients who died in the Basque Country (Spain)","volume":"31","author":"Nu\u00f1o-Solin\u00eds R","year":"2017","unstructured":"Nu\u00f1o-Solin\u00eds R, Herrera Molina E, Librada Flores S, et\u00a0al. Care costs and activity in the last three months of life of cancer patients who died in the Basque Country (Spain). Gac Sanit. 2017;31:524\u2013530.","journal-title":"Gac Sanit"},{"key":"e_1_3_6_30_1","unstructured":"INE. Instituto Nacional de Estad\u00edstica 2022. https:\/\/ine.es\/"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200017050-00006"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.3633"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaceta.2019.06.007"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-520"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.938195"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29030150"},{"key":"e_1_3_6_37_1","first-page":"51","article-title":"Neoadjuvant and adjuvant immunotherapy in Early-Stage Non-Small cell lung cancer","volume":"12","author":"Shukla N","year":"2021","unstructured":"Shukla N, Hanna N. Neoadjuvant and adjuvant immunotherapy in Early-Stage Non-Small cell lung cancer. Lung Cancer. 2021;12:51\u201360.","journal-title":"Lung Cancer"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-527"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23137222"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10235614"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.02.224"},{"key":"e_1_3_6_42_1","doi-asserted-by":"crossref","unstructured":"Chaft JE Dahlberg SE Khullar O V et\u00a0al. EA5142 adjuvant nivolumab in resected lung cancers (ANVIL). 2018;36:TPS8581\u2013TPS8581.","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS8581"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz064.014"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.1437"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.07.429"},{"key":"e_1_3_6_47_1","first-page":"4678","article-title":"Cost-effectiveness analysis of adjuvant therapy with atezolizumab in chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy","volume":"12","author":"Chen P","year":"2022","unstructured":"Chen P, Yang Q, Li Y, et\u00a0al. Cost-effectiveness analysis of adjuvant therapy with atezolizumab in chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy. Front Oncol. 2022;12:4678.","journal-title":"Front Oncol"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2023.2188844","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T10:00:40Z","timestamp":1701943240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2023.2188844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,31]]}},"alternative-id":["10.1080\/13696998.2023.2188844"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2023.2188844","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-01-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}